Telesis Bio

Telesis Bio

TBIO

Telesis Bio is transforming how biology is built by providing automated, in-lab DNA and mRNA synthesis solutions. The company's core technology, including the Gibson Assembly method and the Gibson SOLA enzymatic synthesis platform, empowers researchers to accelerate discovery timelines by up to 93% compared to traditional outsourcing. With a focus on therapeutic applications and a commitment to biosecurity, Telesis Bio serves a global customer base from its San Diego headquarters, enabling faster iteration and greater control in R&D pipelines.

TBIO · Stock Price

USD 0.05-0.24 (-82.41%)
Market Cap: $98K

Historical price data

AI Company Overview

Telesis Bio is transforming how biology is built by providing automated, in-lab DNA and mRNA synthesis solutions. The company's core technology, including the Gibson Assembly method and the Gibson SOLA enzymatic synthesis platform, empowers researchers to accelerate discovery timelines by up to 93% compared to traditional outsourcing. With a focus on therapeutic applications and a commitment to biosecurity, Telesis Bio serves a global customer base from its San Diego headquarters, enabling faster iteration and greater control in R&D pipelines.

Antibody DiscoveryCell & Gene TherapyVaccine DevelopmentSynthetic Biology

Technology Platform

The Gibson SOLA platform is an automated, enzymatic DNA and mRNA synthesis system that builds genetic material in blocks from oligonucleotides, enabling high-fidelity, on-demand production directly in the research lab.

Opportunities

The rapid growth of AI in biology and the need for rapid DNA synthesis to train models presents a major opportunity.
Furthermore, the expansion of cell/gene therapies and mRNA vaccines creates sustained demand for decentralized, high-fidelity DNA/mRNA production capabilities.

Risk Factors

Key risks include slow adoption of capital equipment in research budgets, intense competition from both service providers and new enzymatic synthesis entrants, and the financial pressures of being a small-cap public company in a volatile market.

Competitive Landscape

Main competitors include large gene synthesis service providers (Twist Bioscience, GenScript) and newer enzymatic synthesis startups (DNA Script, Molecular Assemblies). Telesis Bio differentiates with its fully automated, integrated Gibson SOLA platform and its legacy in Gibson Assembly chemistry.